CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players
January 13, 2025 11:45 ET
|
Research and Markets
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added to ...
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
January 13, 2025 09:00 ET
|
ERS Genomics
ERS Genomics (‘ERS’), the CRISPR licensing company, today announces the launch of its Express License platform.
Cytosurge Announces Strategic Leadership Transition
January 09, 2025 10:25 ET
|
Cytosurge AG
Cytosurge appoints Simon Egli as CEO; co-founder Pascal Behr transitions to Board to ensure strategic guidance and growth.
Cell and Gene Therapies Current and Future Landscape 2025-2030
January 02, 2025 05:05 ET
|
Research and Markets
Dublin, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapies - Current and Future Landscape" report has been added to ResearchAndMarkets.com's offering.The global CGT market is expected...
Growth Trends in the CRISPR and Cas Gene Market: Industry Opportunities and Strategies to 2028 & 2033
December 13, 2024 09:27 ET
|
Research and Markets
Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Gene Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.This report describes and...
World’s First Zero-Off-Target Base-edited NK Cell Therapy Receives IND Approval in Both China and the U.S.
December 05, 2024 01:39 ET
|
Base Therapeutics
The world’s first zero-off-target base-edited NK cell product has received IND approvals from both the U.S. FDA and China’s NMPA.
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More
November 29, 2024 04:43 ET
|
Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (GRNA Synthesis & Vector Construction), Technique, Technology...
Exosome Diagnostics & Therapeutics Market Assessment 2025-2030 Featuring Strategic Profiles of the Industry's Leading and Emerging Players
November 28, 2024 06:56 ET
|
Research and Markets
Dublin, Nov. 28, 2024 (GLOBE NEWSWIRE) -- The "Exosome Diagnostics & Therapeutics Market by Product, Application, End User - Global Forecast 2025-2030" report has been added to ...
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
November 25, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies – SNS Insider
November 22, 2024 09:00 ET
|
SNS Insider pvt ltd
Austin, United States, Nov. 22, 2024 (GLOBE NEWSWIRE) -- According to SNS Insider, The Genome Editing Market, valued at USD 7.99 billion in 2023 and is projected to reach USD 32.72 billion by 2032,...